OATP2B1: In Vitro, Proteomic, and Clinical PK Relevance in GI and Liver
Jashvant D. Unadkat, PhD, University of Washington, Seattle, WA

Inhibitor Discovery for the Human GLUT1 from Homology Modeling and Virtual Screening
Avner Schlessinger, PhD, Icahn School of Medicine atMount Sinai, New York, NY

PBPK Modeling of Renal Impairment: What is Missing?
Aleksandra Galetin, PhD, University of Manchester, Manchester, United Kingdom

Na+/Citrate Transporter [SLC13A5] Variants in Epilepsy and Developmental Delay
Ana M. Pajor, PhD, University of California, San Diego, La Jolla, CA

Endogenous Biomarker fo OATP1B: Preclinical to Clinical Translation
Yurong Lai, MD, PhD, Gilead Sciences, Foster City, CA

A European Perspective
Eva Gil Berglund, PhD, Medical Products Agency, Uppsala, Sweden

Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physioloigically-Based Pharmacokinetic Model
Imad Hanna, Novartis Institutes for Biomedical Research, East Hanover, NJ

IVIVE of Transporter-Mediated Clinical Drug-Drug Interactions in Industry –An Update from the IQ Transporter Working Group 
Kari Morrissey, Genentech 

Emerging Importance of Nutrient Transporter-Mediated DDIs--focusing on the thiamine transporters
Yan Zhang, PhD, Incyte Corpration

Induction: Drug Transporters versus Enzymes
Justin D. Lutz, Gilead Sciences, Inc., Foster City, CA

Panel Discussion with Academic, Industry, and Regulatory Scientists
Joseph Polli, PhD, GlaxoSmithKline, King of Prussia, PA